Home › Funds › ARMISTICE CAPITAL, LLC › MDGL

ARMISTICE CAPITAL, LLC position in MDGL

MADRIGAL PHARMACEUTICALS INC · Health Care

ARMISTICE CAPITAL, LLC reported holding 288,000 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$154.6M, representing 2.04% of its reported portfolio and ranking #3 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed MDGL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)288.00K sh
Reported value held$154.64M
Portfolio Weight2.04%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's MDGL position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in MDGL in Q3 2023 at 108,000 shares (US$15.8M). The position peaked in Q4 2025 at 265,705 shares, worth US$154.7M. Across 12 filings, ARMISTICE CAPITAL, LLC increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 288,000 shares valued at US$154.6M — an increase of 23,417 shares quarter over quarter.. Notable position changes include a 236% increase in Q1 2024 (shares rose 5% over the following quarter), a 100% increase in Q4 2024 (shares rose 7% over the following quarter), a 102% increase in Q3 2025 (shares rose 27% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 108.00K $15.77M New
Q4 2023 50.00K $11.57M Reduce
Q1 2024 168.00K $44.86M Add
Q2 2024 150.00K $42.02M Reduce
Q3 2024 49.91K $10.59M Reduce
Q4 2024 100.00K $30.86M Add
Q1 2025 135.88K $45.01M Add
Q2 2025 124.00K $37.53M Reduce
Q3 2025 249.98K $114.66M Add
Q4 2025 265.70K $154.73M Add
Q1 2026 264.58K $138.50M Hold
Q2 2026 288.00K $154.64M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MDGL and 13F data

MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 47 other funds we track also report a position in MDGL — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.15B), RTW INVESTMENTS, LP (US$1.07B), Janus Henderson Group (US$1.05B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MDGL

All MDGL fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held MDGL?

ARMISTICE CAPITAL, LLC has disclosed MDGL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ARMISTICE CAPITAL, LLC's current position in MDGL?

As of Q2 2026, ARMISTICE CAPITAL, LLC holds 288.00K shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $154.64M, representing 2.04% of its reported portfolio and ranking #3.

Has ARMISTICE CAPITAL, LLC been buying or selling MDGL?

In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC increased its position in MDGL. The position peaked in Q4 2025 at 265.70K shares.

Which other funds hold MDGL?

Other major institutional holders of MDGL include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Janus Henderson Group, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.